Cornerstone begins Phase I trial of lymphoma drug candidate CPI-613

Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead drug candidate CPI-613, in combination with bendamustine (Treanda), to treat patients with relapsed or refractory classic Hodgkin's lymphoma (HL) or T-cell non-Hodgkin's lym…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news